Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06304636 · ClinicalTrials.gov registry record · Phase 1
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Cartesian Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT06304636 is a Phase 1 study that was terminated before completion, run by Cartesian Therapeutics. The registered enrollment target is 4 participants.
The verdict
NCT06304636, a Phase 1 study, was terminated before completion, sponsored by Cartesian Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a Phase I dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma. The cell product is referred to as Descartes-15
Interventions
- DRUG Descartes-15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2025-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06304636
The ClinicalTrials.gov registry entry for NCT06304636 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cartesian Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Descartes-15 is the first listed.
NCT06304636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06304636 about?
NCT06304636 is a clinical study titled "Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma". This is a Phase I dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma. The cell product is referred to as Descartes-15
What is the current status of trial NCT06304636?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2024-06-19. Estimated completion is 2025-11-13.
What interventions are being tested in trial NCT06304636?
The interventions under investigation include: Descartes-15 (DRUG).
Who is sponsoring clinical trial NCT06304636?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.